Bristol Myers Squibb gets Reblozyl EC approval for anemia associated with NTD beta thalassemia
Bristol Myers Squibb (BMY) has secured full marketing authorization for Reblozyl (luspatercept) from the European Commission (EC) for treating anemia associated with non-transfusion-dependent (NTD) beta ... Read More
EC approves Reblozyl for transfusion-dependent anemia in adults
Bristol Myers Squibb and Acceleron Pharma have secured approval from the European Commission (EC) for their jointly developed erythroid maturation agent Reblozyl (luspatercept) for the ... Read More
Celgene, Acceleron bag Reblozyl FDA approval for anemia in beta thalassemia
Reblozyl FDA approval : Celgene and Acceleron Pharma have bagged approval from the US Food and Drug Administration (FDA) for Reblozyl (luspatercept-aamt) for the treatment ... Read More